دورية أكاديمية

Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long‐Term Ticagrelor in Stable Patients With Prior Myocardial Infarction

التفاصيل البيبلوغرافية
العنوان: Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long‐Term Ticagrelor in Stable Patients With Prior Myocardial Infarction
المؤلفون: Giulia Magnani, Diego Ardissino, KyungAh Im, Andrzej Budaj, Robert F. Storey, P. Gabriel Steg, Deepak L. Bhatt, Marc Cohen, Ton Oude Ophius, Assen Goudev, Alexander Parkhomenko, Gabriel Kamensky, Dominick J. Angiolillo, José López‐Sendón, Per Johanson, Eugene Braunwald, Marc S. Sabatine, Marc P. Bonaca
المصدر: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 4 (2021)
بيانات النشر: Wiley, 2021.
سنة النشر: 2021
المجموعة: LCC:Diseases of the circulatory (Cardiovascular) system
مصطلحات موضوعية: benefit‐risk ratio, bleeding, long‐term ticagrelor, myocardial infarction, Diseases of the circulatory (Cardiovascular) system, RC666-701
الوصف: Background Ticagrelor reduces ischemic risk but increases bleeding in patients with prior myocardial infarction. Identification of patients at lower bleeding risk is important in selecting patients who are likely to derive more favorable outcomes versus risk from this strategy. Methods and Results PEGASUS‐TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin—Thrombolysis in Myocardial Infarction 54) randomized 21 162 patients with prior myocardial infarction in a 1:1:1 fashion to ticagrelor 60 mg or 90 mg twice daily or placebo, with ticagrelor 60 mg approved for long‐term use. TIMI major or minor bleeding was the primary end point for this analysis. Causes of bleeding were categorized by site and etiology, and independent predictors were identified. At 3 years, ticagrelor 60 mg increased the rate of TIMI major or minor bleeding by 2.0% versus placebo (1.4% placebo versus 3.4% ticagrelor). The bleeding excess was driven primarily by spontaneous gastrointestinal bleeds. A history of spontaneous bleeding requiring hospitalization and the presence of anemia were independent predictors of bleeding but not of ischemic risk. Patients with at least 1 risk predictor had 3‐fold higher rates of bleeding with ticagrelor 60 mg versus those who had neither (absolute risk increase, 4.4% versus 1.5%; P=0.01). Patients with neither predictor had a more favorable benefit profile with ticagrelor 60 mg versus placebo including lower mortality (hazard ratio, 0.79; 95% CI, 0.65–0.96; P interaction = 0.03). Conclusions In patients with prior myocardial infarction, bleeding with ticagrelor 60 mg twice daily is predominantly spontaneous gastrointestinal. A history of spontaneous bleeding requiring hospitalization or the presence of anemia identifies patients at higher risk of bleeding, and the absence of either identifies patients likely to have a more favorable net benefit with ticagrelor. Registration URL https://www.clinicaltrials.gov/. Unique identifier: NCT01225562.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2047-9980
Relation: https://doaj.org/toc/2047-9980
DOI: 10.1161/JAHA.120.017008
URL الوصول: https://doaj.org/article/380c3bd2158546a98fc3e85a0f10d67e
رقم الأكسشن: edsdoj.380c3bd2158546a98fc3e85a0f10d67e
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:20479980
DOI:10.1161/JAHA.120.017008